| 41.08 -0.44 (-1.06%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 49.23 | 1-year : | 51.49 |
| Resists | First : | 42.15 | Second : | 44.09 |
| Pivot price | 40.7  |
|||
| Supports | First : | 39.02 | Second : | 32.47 |
| MAs | MA(5) : | 41.14 |
MA(20) : | 41.06 |
| MA(100) : | 43.04 |
MA(250) : | 43 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 83 |
D(3) : | 74.4 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 47.7 | Low : | 34.74 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ QGEN ] has closed below upper band by 39.9%. Bollinger Bands are 34.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41.13 - 41.36 | 41.36 - 41.54 |
| Low: | 40 - 40.29 | 40.29 - 40.52 |
| Close: | 40.65 - 41.09 | 41.09 - 41.45 |
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Thu, 25 Apr 2024
Following a 5.6% decline over last year, recent gains may please Qiagen N.V. (NYSE:QGEN) institutional owners - Simply Wall St
Wed, 24 Apr 2024
Unveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key Metrics - Zacks Investment Research
Mon, 22 Apr 2024
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Movies Canada
Sun, 21 Apr 2024
QIAGEN's (QGEN) NeuMoDx Multiplex Test Receives FDA EUA - Yahoo Movies Canada
Tue, 09 Apr 2024
QIAGEN N.V. to release results for Q1 2024 and hold webcast - Yahoo Finance
Tue, 09 Apr 2024
QIAGEN N.V. to release results for Q1 2024 and hold - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 221 (M) |
| Shares Float | 219 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 74.4 (%) |
| Shares Short | 3,560 (K) |
| Shares Short P.Month | 3,070 (K) |
| EPS | 1.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.2 |
| Profit Margin | 17.3 % |
| Operating Margin | 23.8 % |
| Return on Assets (ttm) | 4.4 % |
| Return on Equity (ttm) | 9.3 % |
| Qtrly Rev. Growth | 2.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 8.89 |
| EBITDA (p.s.) | 2.88 |
| Qtrly Earnings Growth | 8.8 % |
| Operating Cash Flow | 459 (M) |
| Levered Free Cash Flow | 157 (M) |
| PE Ratio | 27.02 |
| PEG Ratio | 11.2 |
| Price to Book value | 2.38 |
| Price to Sales | 4.61 |
| Price to Cash Flow | 19.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|